Benitec Biopharma Inc. Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
Benitec Biopharma Inc. (BNTC) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $6.27 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-14.
Financial Statements › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2026-09-14
- Benitec Biopharma Inc. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2025-12-31 was $6.26M.
- Benitec Biopharma Inc. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2025-03-31 was $2.25M.
- Benitec Biopharma Inc. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2026 was $6.27M, a 178.24% increase from fiscal 2025.
- Benitec Biopharma Inc. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2025 was $2.25M.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 3 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month |
|---|---|---|
| 2026-06-30 | $6.27M 10-K · filed 2026-09-14 | |
| 2025-12-31 | $6.26M 10-Q · filed 2026-05-14 | |
| 2025-06-30 | $2.25M 10-K · filed 2026-09-14 | |
| 2025-03-31 | $2.25M 10-Q · filed 2026-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |